NASDAQ:IDXX - IDEXX Laboratories Stock Price, News, & Analysis

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories declared that its board has authorized a share repurchase program on Sunday, June 4th 2017, which permits the company to buyback 3,000,000 outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's board believes its shares are undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings results on Wednesday, August, 1st. The company reported $1.23 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.17 by $0.06. The company earned $580.75 million during the quarter, compared to the consensus estimate of $574.68 million. IDEXX Laboratories had a net margin of 14.50% and a negative return on equity of 703.80%. The business's revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter last year, the company posted $0.87 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided earnings per share (EPS) guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus estimate of $4.15. The company issued revenue guidance of $2.205-2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

6 brokerages have issued twelve-month price targets for IDEXX Laboratories' stock. Their forecasts range from $215.00 to $260.00. On average, they anticipate IDEXX Laboratories' stock price to reach $238.00 in the next twelve months. This suggests that the stock has a possible downside of 1.8%. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX) and Vermillion (VRML).

News stories about IDXX stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IDEXX Laboratories earned a news and rumor sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 45.59 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for IDEXX Laboratories.

IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.25%), Renaissance Technologies LLC (2.51%), Bank of New York Mellon Corp (1.28%), American Century Companies Inc. (0.96%), Bank of America Corp DE (0.84%) and CIBC Private Wealth Group LLC (0.60%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Columbus Circle Investors, Wells Fargo & Company MN, Bank of America Corp DE, Janus Henderson Group PLC, FMR LLC, Federated Investors Inc. PA and TCW Group Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Ardevora Asset Management LLP, Worldquant Millennium Quantitative Strategies LLC, CIBC Private Wealth Group LLC, First Trust Advisors LP, Renaissance Technologies LLC, Baird Financial Group Inc. and Schroder Investment Management Group. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $242.48.

IDEXX Laboratories has a market capitalization of $21.09 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]